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Abstract
Objective
This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA
for the treatment of chronic sialorrhea due to Parkinson disease (PD), atypical parkinsonism,
stroke, or traumatic brain injury (TBI).
Methods
Adult patients with PD (70.7%), atypical parkinsonism (8.7%), stroke (19.0%), or TBI (2.7%)
were randomized (2:2:1) to double-blind treatment with placebo (n = 36), or total doses of
incobotulinumtoxinA 75U (n = 74) or 100U (n = 74), in a single treatment cycle. The coprimary
endpoints were change in unstimulated salivary flow rate from baseline to week 4, and patients’
Global Impression of Change Scale score at week 4. Adverse events were recorded throughout.
Results
A total of 184 patients were randomized. Both incobotulinumtoxinA dose groups showed
reductions inmean unstimulated salivary flow rate at week 4, with a significant difference vs placebo
in the incobotulinumtoxinA 100U group (p = 0.004). Patients’Global Impression of Change Scale
scores also improved at week 4, with a significant difference vs placebo in the incobotulinumtoxinA
100U group (p= 0.002). A lasting effect was observed at week 16 post injection. Themost frequent
treatment-related adverse events in the incobotulinumtoxinA 75 U and 100 U groups were dry
mouth (5.4% and 2.7% of patients) and dysphagia (2.7% and 0.0% of patients).
Conclusions
IncobotulinumtoxinA 100 U is an effective and well-tolerated treatment of chronic sialorrhea in
adults.
ClinicalTrials.gov identifier
NCT02091739.
Classification of evidence
This study provides Class I evidence that incobotulinumtoxinA reduces salivary flow rates in
patients with chronic sialorrhea due to PD, atypical parkinsonism, stroke, or TBI.
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Intractable sialorrhea (drooling; overflowing saliva from the
mouth, over the lip margin, or through the pharynx) is
a troublesome and disabling symptom resulting from various
causes, such as swallowing problems or an inability to retain
saliva in the mouth. Sialorrhea is frequently associated with
underlying diseases including cerebral palsy,1 Parkinson dis-
ease (PD),2,3 amyotrophic lateral sclerosis (ALS),4 traumatic
brain injury (TBI),5 stroke, and various degenerative brain
disorders.6
Prevalence rates for sialorrhea in patients with PD range from
32% to 74%.3 The effects of sialorrhea range from adverse
effects on caregiver quality of life7 and patient quality of life,
ranging from difficulty eating and speaking with social and
emotional consequences,2,8,9 to an increased risk of morbidity
and mortality associated with perioral skin breakdown and
aspiration pneumonia.10 Treatment approaches are based on
multidisciplinary management of drooling and, at the time
this study was conducted, no pharmacologic agents had US
Food and Drug Administration or European Medicines
Agency approval for the treatment of chronic sialorrhea in
adults. However, botulinum neurotoxin type A (BoNT/A)
had been effectively used to reduce saliva production in
patients with sialorrhea since 1999,11,12 and numerous studies
had demonstrated the safety and efficacy of BoNT/A and /B
formulations for sialorrhea in patients with PD and ALS.13–22
This pivotal phase III study investigated the efficacy and safety
of incobotulinumtoxinA (75 U and 100 U) for the treatment
of sialorrhea due to PD, atypical parkinsonism, stroke, or TBI.
Results from a single treatment cycle in the placebo-
controlled main period (MP) are reported.
Methods
Study design
SIAXI (Sialorrhea in Adults Xeomin Investigation) was
a prospective, randomized, double-blind, placebo-controlled,
parallel-group, multicenter study conducted over 33 sites (12
sites in Germany and 21 sites in Poland).
After an initial clinical screening visit to determine the
patient’s eligibility for inclusion in the study, patients were
randomly assigned (2:2:1) in a double-blind manner (using
an interactive web response system) to receive total doses
of incobotulinumtoxinA (BoNT/A free from complexing
proteins; Xeomin, Merz Pharmaceuticals GmbH, Frankfurt
am Main, Germany) 75 U or 100 U or placebo in a single
treatment (MP), and incobotulinumtoxinA doses of 75 U or
100 U in 3 further treatments (extension period) at 16-week
intervals, each of them followed by regular monitoring during
16 ± 2 weeks of observation for a total of 64 weeks. Only the
data from the placebo-controlled MP are presented here.
In each cycle, treatment was administered in 4 injections,
bilaterally into the parotid and submandibular salivary glands
(one injection for each gland, guided by ultrasound23 or an-
atomical landmarks) as follows:
c In the 75 U group, 22.5 U (0.6 mL) and 15 U (0.4 mL),
respectively, per side
c In the 100 U group, 30 U (0.6 mL) and 20 U (0.4 mL),
respectively, per side
c Equivalent volumes were injected into each gland in the
placebo group. Placebo contained excipients of incobo-
tulinumtoxinA injection, sucrose, and human serum
albumin to control for any physiologic effects of these
carrier molecules in the standard incobotulinumtoxinA
preparation.
Standard protocol approvals, registrations,
and patient consents
The study was registered in the database of the US National
Library of Medicine (clinicaltrials.gov), record number
NCT02091739, and the EU Clinical Trials Register (eudract.
ema.europa.eu/), EudraCT record number 2012-005539-10,
and conducted in accordance with the ethical principles out-
lined in the Declaration of Helsinki. The study protocol, in-
formed consent forms, and other study-related documents
were reviewed and approved by the local independent ethics
committees and institutional review boards. Written informed
consent was obtained from all patients; if patients were phys-
ically unable to give written consent, oral consent was con-
firmed in writing by an impartial witness.
Study population
Adult patients with a documented diagnosis (≥6 months prior
to screening) of idiopathic or familial PD (according to the
United Kingdom Parkinson’s Disease Brain Bank [parkinsons.
org.uk] diagnostic criteria), atypical parkinsonism (comprising
multiple system atrophy, progressive supranuclear palsy, or
corticobasal degeneration), stroke, or TBI were included in this
study. Patients were required to have chronic troublesome
sialorrhea related to their primary neurologic diagnosis
continuously for ≥3 months prior to screening, defined as
a Drooling Severity and Frequency Scale (DSFS) sum score
Glossary
AE = adverse event; AESI = adverse event of special interest; ALS = amyotrophic lateral sclerosis; BoNT = botulinum
neurotoxin; DSFS = Drooling Severity and Frequency Scale; GICS = Global Impression of Change Scale; LS-means = least
squares means;MMRM =mixed model repeated measurement;MP =main period;mROMP =modified Radboud Oral Motor
Inventory for Parkinson’s Disease; PD = Parkinson disease; SIAXI = Sialorrhea in Adults Xeomin Investigation; TBI =
traumatic brain injury; uSFR = unstimulated salivary flow rate.
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of ≥6 points; a score of ≥2 points for each item of the DSFS;
and a score of ≥3 points on the modified Radboud Oral
Motor Inventory for Parkinson’s Disease (mROMP)
drooling Item A at screening and baseline. In addition,
patients were required to have a score of ≤2 and ≤3 points on
the mROMP swallowing symptoms Items A and C, re-
spectively, at screening and baseline. The original ROMP
questionnaire24 was developed by the Radboud University
Medical Centre in Nijmegen, the Netherlands, and was
modified to implement small changes in wording (to extend
the use of the scale in patients with sialorrhea in general,
including those with stroke and TBI) resulting from patient
interviews during linguistic validation in US English.
mROMP is a 24-item inventory in which the domains of
speech symptoms, swallowing symptoms, and drooling are
assessed using a 5-point Likert scale. Permission to use the
questionnaire for this study was granted by the Radboud
University Medical Centre. Results of the analysis of
mROMP data are reported separately.
The main exclusion criteria were secondary causes of sialor-
rhea other than parkinsonism, stroke, or TBI; drug treatment
for sialorrhea within 4 weeks prior to baseline or planned
during the MP; unstable concomitant medication that may
influence sialorrhea; changes to antiparkinsonian medication
within 4 weeks of screening; a history of recurrent aspiration
pneumonia; prior recent treatment with, or hypersensitivity
to, BoNT (within 1 year for sialorrhea or 14 weeks for other
indications); and surgery (previous or planned) for sialorrhea.
Outcome measures
The coprimary endpoints were the change in unstimulated
salivary flow rate (uSFR) from study baseline to week 4, and
the patients’ Global Impression of Change Scale (GICS)
score at week 4. The change in uSFR from study baseline to
weeks 8 and 12, and patients’GICS score at weeks 1, 2, 8, and
12 were assessed as secondary endpoints. The change in uSFR
from study baseline to week 16 and patients’ GICS score at
week 16 were assessed as other efficacy variables.
Unstimulated salivary flow rate
The uSFR was measured from direct saliva collection using
the swab method. Briefly, 1 hour before the measurement, the
patient’s teeth were brushed and the patient was not allowed
to eat or smoke until after the measurement had been taken.
Patients were offered a drink of mineral water 30 minutes
before the measurement.
For the measurement, 4 adsorbent Salimetrics Oral Swabs
(2-mL capacity; Salimetrics, Carlsbad, CA) were placed at the
orifices of the salivary glands (between cheek and gum, and
between tongue and gum at each side of themouth) and left for
5minutes to absorb the saliva produced. The weight increase of
the swabs was used to calculate the salivary flow rate in grams/
minute (based on a precision of 0.01 g and a real-time duration
in minutes and seconds). The procedure was repeated after 30
minutes and the average of 2 results was calculated.
Global Impression of Change Scale
The patients’ and carers’ GICS score was measured on
a 7-point Likert scale that ranged from −3 (very much worse)
to +3 (very much improved) in response to the following self-
administered questions:
c For patients: “Compared to how you were doing just
before the last injection into your salivary gland, what is
your overall impression of how you are functioning now
as a result of this treatment?”
c For caregivers: “Compared to how the patient was doing
just before the last injection into his/her salivary gland, what
is your overall impression of how he/she is functioning now
as a result of this treatment?”
Other endpoints
Investigators rated the change in drooling severity and fre-
quency from study baseline to all posttreatment visits using
the DSFS.25 DSFS comprises 2 subscales for drooling severity,
measured on a 5-point Likert scale from 1 (dry; never drools)
to 5 (profuse; hands, tray, and objects wet) and drooling
frequency, measured on a 4-point Likert scale from 1 (never)
to 4 (constantly). The DSFS sum score was calculated from
the sum of the 2 subscales, maximum score 9.
The occurrence of adverse events (AEs), AEs related to
treatment, AEs of special interest (AESIs) possibly indicative
of toxin spread, and serious AEs, based on MedDRA (Medical
Dictionary for Regulatory Activities) version 19.1, was recorded.
Statistical analysis
A total of 180 treatment-naive patients were planned to be
randomized in order to achieve 95% power to show a statisti-
cally significant difference between the active treatment groups
and placebo for both of the coprimary endpoints and to have at
least 100 patients treated with incobotulinumtoxinA and ob-
served over 1 year (anticipating a 30% dropout rate over 1 year).
Efficacy analyses were based on the full analysis set, defined as
all patients whowere treated and had at least a baseline value for
uSFR. Safety data were based on the safety evaluation set, de-
fined as all patients who received incobotulinumtoxinA or pla-
cebo during the MP, and analyzed using descriptive statistics.
A fixed-sequence test procedure was performed for the
coprimary efficacy variables, first comparing the incobotuli-
numtoxinA 100 U treatment group with placebo, followed by
comparison of the 75 U group with placebo if results of the
first tests were significant. Changes from baseline in copri-
mary and secondary efficacy variables were assessed by
a mixed model repeated measurement (MMRM) analysis;
p values of <0.05 were considered to be statistically significant.
Independent variables were defined as treatment group, eti-
ology, use of ultrasound injection guidance, country and sex as
fixed factor, visit * treatment as interaction term, and visit as
repeated factor. The DSFS sum score was analyzed analo-
gously to the coprimary efficacy variables.
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Confirmatory analyses were conducted using comparison of
least squares means (LS-means) of the MMRM model, and
sensitivity analyses were performed using analysis of co-
variance models and nonparametric tests.
Classification of evidence
This prospective, randomized, double-blind, placebo-controlled
study assessed the efficacy and safety of incobotulinumtoxinA
(75 and 100 U) for reduction of salivary flow rate, and severity
and frequency of chronic, troublesome sialorrhea. This study
provides Class I evidence that incobotulinumtoxinA reduces
salivary flow rates in patients with chronic sialorrhea due to PD,
atypical parkinsonism, stroke, or TBI.
Data availability
No individual deidentified participant data are shared. Key
elements of the study protocol, study design, and statistical
analysis plan were deposited in the database of the US Na-
tional Library of Medicine, record number NCT02091739,
and the EU Clinical Trials Register, EudraCT record number
2012-005539-10. All relevant information is contained within
this report and supplemental materials.
Results
Study population
A total of 184 patients were randomized in the study and
received either placebo (n = 36), or incobotulinumtoxinA
75 U (n = 74) or 100 U (n = 74) (figure 1). Overall, 11
patients (6.0%) discontinued and 173 patients (94.0%)
completed the MP. The reasons for discontinuation were
withdrawal by patient (n = 8), AEs not related to treatment
(n = 3), physician decision (n = 2), and/or lost to follow-up
(n = 1); multiple reasons for withdrawal could be listed
(figure 1).
Baseline characteristics for each treatment group and the total
population are summarized in table 1. Drooling etiology and
baseline demographics were similar in all treatment groups.
Most patients (130 [70.7%]) had sialorrhea due to PD; sia-
lorrhea was due to atypical parkinsonism, stroke, and TBI in 16
(8.7%), 33 (17.9), and 5 (2.7%) patients, respectively. Among
146 patients with PD or atypical parkinsonism, the mean (SD)
Unified Parkinson’s Disease Rating Scale section III “motor
examination” score was 31.2 (15.6) at baseline, indicating
moderate to severe impairment. The salivary flow rate was in
the normal expected range for this patient population: at
baseline, the mean (SD) uSFR was 0.40 (0.26) g/min and the
mean (SD) DSFS score was 6.86 (0.93) (table 1) indicating
moderate to severe troublesome sialorrhea on average.
Salivary glands were localized and injections were adminis-
tered using ultrasound guidance in 56.5% of patients in the
total population and at least 50.0% in each treatment group,
with no difference in baseline demographics or severity of
sialorrhea in patients who received ultrasound or anatomical
landmark–guided injection (data not shown).
As expected in this patient population, the most frequent
comorbidities in the placebo, incobotulinumtoxinA 75 U, and
incobotulinumtoxinA 100 U groups were nervous system
disorders (94.4%, 94.6%, and 87.8%, respectively), vascular
Figure 1 Disposition of patients for the MP of the study
An AE leading to discontinuation occur-
ring in one placebo patient was not con-
sidered a treatment-emergent AE (AE
with onset or worsening at or after
treatment). aMultiple reasons for with-
drawal could be listed; bAEs were not
treatment-related. AE = adverse event;
MP = main period.
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disorders (61.1%, 58.1%, and 56.8%, respectively), metabo-
lism and nutrition disorders (38.9%, 52.7%, and 41.9%, re-
spectively), and musculoskeletal and connective tissue
disorders (41.7%, 41.9%, and 41.9%, respectively).
Unstimulated salivary flow rate
Compared with placebo, both active treatment groups
showed a numerical reduction in mean uSFR at week 4 (figure
2A). From baseline to 4 weeks post treatment, the LS-mean
(standard error [SE]) difference vs placebo was −0.02 (0.030;
p = 0.542, MMRM analysis) and −0.09 (0.031; p = 0.004,
MMRM analysis) g/min in the incobotulinumtoxinA 75 U
and incobotulinumtoxinA 100 U groups, respectively. Sensi-
tivity analyses confirmed the efficacy of the 100 U dose. The
use of ultrasound guidance, included as an independent var-
iable in statistical analysis, did not confound results.
Secondary analyses revealed reductions in uSFR from baseline
to 8 and 12 weeks post treatment in both active treatment
groups (figure 2A). Significant reductions in uSFR compared
with placebo were noted in both active treatment groups
at week 8 (LS-mean [SE] difference vs placebo: incobotuli-
numtoxinA 75 U, −0.07 [0.029] g/min; p = 0.022, and inco-
botulinumtoxinA 100 U, −0.12 [0.030] g/min; p < 0.001,
MMRM analysis) and week 12 (LS-mean [SE] difference vs
placebo: incobotulinumtoxinA 75 U, −0.07 [0.031] g/min; p =
0.019, and incobotulinumtoxinA 100 U, −0.09 [0.031] g/min;
p = 0.004, MMRM analysis). In patients treated with incobo-
tulinumtoxinA 100 U, significant reductions vs placebo were
maintained at the last observation point at week 16 (LS-mean
[SE] difference vs placebo: incobotulinumtoxinA 75 U, −0.04
[0.033] g/min; p = 0.180, and incobotulinumtoxinA 100 U,
−0.10 [0.033] g/min; p = 0.002, MMRM analysis) (figure 2A).
GICS score
Compared with placebo, both active treatment groups showed
greater improvement as measured by patients’ GICS score at
week 4 (figure 2B). The LS-mean (SE) difference vs placebo
was 0.35 (0.181; p = 0.055, MMRM analysis) and 0.58 (0.183;
p = 0.002, MMRM analysis) in the incobotulinumtoxinA 75 U
Table 1 Patient demographics and baseline characteristics
Characteristic
Placebo
(n = 36)
IncobotulinumtoxinA
75 U (n = 74)
IncobotulinumtoxinA
100 U (n = 74) Total (N = 184)
Sex, n (%)
Male 28 (77.8) 50 (67.6) 52 (70.3) 130 (70.7)
Female 8 (22.2) 24 (32.4) 22 (29.7) 54 (29.3)
Age, y, mean (SD) 63.5 (10.6) 65.2 (11.7) 66.0 (11.6) 65.2 (11.4)
Weight, kg, mean (SD) 80.6 (16.4) 78.4 (17.1) 79.8 (14.0) 79.4 (15.7)
BMI, kg/m2, mean (SD) 28.5 (6.0) 26.7 (5.2) 27.7 (3.8) 27.5 (4.9)
Drooling etiology, n (%)
PD 26 (72.2) 51 (68.9) 53 (71.6) 130 (70.7)
Atypical parkinsonism 3 (8.3) 8 (10.8) 5 (6.8) 16 (8.7)
Stroke 6 (16.7) 13 (17.6) 14 (18.9) 33 (17.9)
Traumatic brain injury 1 (2.8) 2 (2.7) 2 (2.7) 5 (2.7)
UPDRS section III score, mean (SD) [n] 29.2 (12.7) [29] 33.1 (17.2) [59] 30.3 (15.1) [58] 31.2 (15.6) [146]
uSFR, g/min, mean (SD) 0.38 (0.23) 0.42 (0.28) 0.40 (0.27) 0.40 (0.26)
DSFS score, mean (SD) 6.97 (1.06) 6.88 (0.91) 6.78 (0.90) 6.86 (0.93)
Concomitant anti-PDmedication, n (%)a
Dopaminergic agents 28 (77.8) 57 (77.0) 58 (78.4) 143 (77.7)
Anticholinergic agentsb 0 (0.0) 2 (2.7) 2 (2.7) 4 (2.2)
Injection guidance, n (%)
Ultrasound-guided 18 (50.0) 45 (60.8) 41 (55.4) 104 (56.5)
Anatomical landmark–guided 18 (50.0) 29 (39.2) 33 (44.6) 80 (43.5)
Abbreviations: BMI = bodymass index; DSFS =Drooling Severity and Frequency Scale; PD = Parkinson disease; UPDRS section III = Unified Parkinson’s Disease
Rating Scale section III “motor examination” for patients with PD and atypical parkinsonism; uSFR = unstimulated salivary flow rate.
a Stable dose in patients with PD and atypical parkinsonism.
b Four patients were treated with biperiden during the main phase.
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and 100 U groups, respectively. Sensitivity analyses supported
these results. The use of ultrasound guidance, included as an
independent variable in statistical analysis, did not confound
results.
Secondary analyses showed improvement with incobotuli-
numtoxinA 100 U vs placebo at 1 and 2 weeks post treatment
as measured by patients’GICS score. Significant improvements
vs placebo were shown in both active treatment groups at week
8 (LS-mean [SE] difference vs placebo: incobotulinumtoxinA
75U, 0.61 [0.190]; p = 0.002, and incobotulinumtoxinA 100U,
0.84 [0.192]; p < 0.001, MMRM analysis) and week 12 (LS-
mean [SE] difference vs placebo: incobotulinumtoxinA 75 U,
0.42 [0.200]; p = 0.035, and incobotulinumtoxinA 100 U, 0.65
[0.201]; p = 0.001, MMRM analysis). In patients treated with
incobotulinumtoxinA 100 U, significant improvements vs pla-
cebo were maintained at the last observation point at week 16
(LS-mean [SE] difference vs placebo: incobotulinumtoxinA 75
U, 0.13 [0.203]; p = 0.531, and incobotulinumtoxinA 100 U,
0.52 [0.203]; p = 0.011, MMRM analysis) (figure 2B).
DSFS sum score
Significant improvements from baseline in DSFS sum score
compared with placebo were noted in both active treatment
groups at week 4 (LS-mean [SE] difference vs placebo:
incobotulinumtoxinA 75 U, −0.88 [0.275]; p = 0.002, and
Figure 2 Clinical outcomes over time
(A) Change in uSFR from baseline to weeks 4, 8, 12, and 16; (B)
patients’GICS score atweeks 1, 2, 4, 8, 12, and 16; and (C) change in
DSFS sum score from baseline to weeks 4, 8, 12, and 16 post
treatment. *p < 0.05, **p < 0.01, ***p ≤ 0.001, mixed model re-
peated measurement analysis based on change from baseline vs
placebo in panels A and C, and the rating at each posttreatment
assessment vs placebo in panel B. Reduction in uSFR and DSFS
indicates improvement. GICS score: −3 (very much worse), −2
(much worse), −1 (minimally worse), 0 (no change in function), +1
(minimally improved), +2 (much improved) to +3 (very much im-
proved). DSFS = Drooling Severity and Frequency Scale; GICS =
Global Impression of Change Scale; LS-mean = least squares
mean; SE = standard error; uSFR = unstimulated salivary flow rate.
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incobotulinumtoxinA 100 U, −1.17 [0.278]; p < 0.001,
MMRM analysis; figure 2C). Significant improvements vs
placeboweremaintained at week 8 (LS-mean [SE] difference vs
placebo: incobotulinumtoxinA 75 U, −0.93 [0.289]; p = 0.002,
and 100 U, −1.29 [0.291]; p < 0.001, MMRM analysis) and
week 12 post treatment (LS-mean [SE] difference vs placebo:
incobotulinumtoxinA 75 U, −0.77 [0.284]; p = 0.008, and
100 U, −0.63 [0.286]; p = 0.030, MMRM analysis) (figure 2C).
Safety
AEs were reported in 15 (41.7%), 32 (43.2%), and 34 (45.9%)
patients in the placebo, incobotulinumtoxinA 75 U, and 100 U
groups, respectively. Serious AEs, none of which were deemed
to be related to treatment, were reported in 3 (8.3%), 6 (8.1%),
and 9 (12.2%) patients, respectively.
AEs that were deemed to be related to treatment occurred in
3 (8.3%), 7 (9.5%), and 6 (8.1%) patients in the placebo,
incobotulinumtoxinA 75 U, and 100 U groups, respectively
(table 2); all were nonserious and of mild or moderate in-
tensity. The most frequent treatment-related AEs were dry
mouth (occurring in 4 [5.4%] and 2 [2.7%] patients in the
incobotulinumtoxinA 75 U and 100 U groups, respectively)
and dysphagia (occurring in 2 [2.7%] patients in the inco-
botulinumtoxinA 75 U group and no patients in the 100 U
group). All patients who experienced treatment-related dry
mouth and treatment-related dysphagia had sialorrhea due to
PD. No patients receiving concomitant anticholinergic med-
ication reported dry mouth.
Five patients each (6.8%) in the incobotulinumtoxinA 75 U
and 100 U groups experienced AESIs, including dysphagia (3
patients [4.1%] in the 75 U group), dry mouth and dysphonia
(2 patients each [2.7%] in the 100 U group), dysarthria (1
patient [1.4%] in the 100 U group), speech disorder, brady-
cardia, and eyelid ptosis (one patient each [1.4%] in the 75 U
group). Of these, 2 events of dysphagia, and one of dry mouth,
speech disorder, and eyelid ptosis were deemed related to
treatment. One event each of dysphonia and dysarthria were
of severe intensity but not deemed related to treatment. No
patients in the placebo group experienced AESIs. All patients
who experienced dysphagia as an AESI had PD, and 2 of the 3
patients had preexisting dysphagia.
AEs led to discontinuation in 2 patients: pneumonia in one
patient in the 75 U group and gastrointestinal obstruction in
one patient in the 100 U group. Both events were of severe
intensity, were not related to treatment, and were resolved
with sequelae (gastrostomy and tracheotomy, and substantial
problems walking following surgery for inguinal hernia, re-
spectively) at the end of the study. No fatal events occurred.
Discussion
The results presented here provide Level I evidence in sup-
port of incobotulinumtoxinA as an effective targeted treat-
ment for chronic sialorrhea in adults. The reduction in uSFR
and improvement in GICS score compared with placebo 4
Table 2 Summary of AEs
Patients
Placebo
(n = 36)
IncobotulinumtoxinA,
75 U (n = 74)
IncobotulinumtoxinA,
100 U (n = 74)
Total incobotulinumtoxinA
(N=148)
Any AE 15 (41.7) 32 (43.2) 34 (45.9) 66 (44.6)
Any treatment-related AE 3 (8.3) 7 (9.5) 6 (8.1) 13 (8.8)
Any AESIa 0 (0.0) 5 (6.8) 5 (6.8) 10 (6.8)
Any treatment-related AESI 0 (0.0) 3 (4.1) 1 (1.4) 4 (2.7)
Any SAE 3 (8.3) 6 (8.1) 9 (12.2) 15 (10.1)
Any treatment-related SAE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any AE leading to discontinuationb 0 (0.0) 1 (1.4) 1 (1.4) 2 (1.4)
Any treatment-related AE leading to
discontinuation
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any fatal AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any fatal treatment-related AE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: AE = adverse event; AESI = adverse event of special interest; SAE = severe adverse event.
Data represent number of patients, n (%). AEs in themain period were defined as AEs with onset or worsening after the first injection of incobotulinumtoxinA
or placebo up to and before the first injection of the extension period.
a AESIs were classified based on a predefined list of AEs that could potentially indicate toxin spread (MedDRA version 19.1), regardless of whether an AE was
regarded as treatment-related by the investigator. AESIs occurring in the incobotulinumtoxinA 75 U and 100 U groups, respectively, were as follows:
dysphagia (n = 3 [2 related], n = 0); dry mouth (n = 0, n = 2 [1 related]); dysarthria (n = 0, n = 1); speech disorder (n = 1 [related], n = 0); dysphonia (n = 0, n = 2);
bradycardia (n = 1, n = 0); and eyelid ptosis (n = 1 [related], n = 0). AEs describing dry mouth considered to be severe, serious, or irreversible were reported as
AESIs.
b AEs leading to discontinuation were gastrointestinal obstruction and pneumonia of a severe intensity, not related to treatment.
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weeks post treatment (coprimary endpoints) reached statis-
tical significance for the incobotulinumtoxinA 100 U group,
with efficacy confirmed by secondary and other endpoints. In
addition, both doses of incobotulinumtoxinA (75 U and 100
U) were well tolerated, with a similar incidence of treatment-
related AEs to the placebo group. These data led to the recent
US Food and Drug Administration approval of incobotuli-
numtoxinA 100 U for the treatment of chronic sialorrhea in
adult patients.26
Until recently, treatment approaches were based on a multi-
disciplinary management of symptoms, including speech
therapy, oral motor training, swallowing training, oral anti-
cholinergics, and BoNT injections in the salivary glands to
reduce the amount of saliva produced daily.27–29 In therapy-
resistant cases, irradiation or salivary gland surgery can be
used to reduce functional salivary gland tissue or to relocate
salivary ducts.27 Anticholinergics, used to reduce the motor
symptoms of PD, reduce saliva production by inhibiting the
action of acetylcholine at muscarinic receptors. For example,
glycopyrrolate is recommended for the treatment of sialor-
rhea for up to 1 week.29 However, the nonspecific, systemic
activity of these treatments is associated with frequently ob-
served adverse effects (including cognitive impairment,
drowsiness, and urinary retention), limiting their use for the
treatment of chronic sialorrhea.27,29 Following positive
reports of BoNT/A in the treatment of sialorrhea,17,18 the
efficacy and safety of incobotulinumtoxinA for the treatment
of sialorrhea of various causes has been investigated in small
pilot studies or case reports.30–34
The findings of this large, pivotal, phase III, randomized,
double-blind, placebo-controlled study are consistent with
those of previous small exploratory studies that showed a re-
duction of sialorrhea in adults with neurologic disorders in-
cluding PD and ALS treated with onabotulinumtoxinA, at
a mean dose of 76.6 U per patient18 or 50 U per parotid
gland,15 incobotulinumtoxinA at ≤100 U,31,32 or onabotuli-
numtoxinA or incobotulinumtoxinA up to 100 U total dose
into 2, 3, or 4 glands.35 A similar subjective improvement in
sialorrhea measured by DSFS was reported in a placebo-
controlled study of 36 patients with advanced-phase PD
treated with rimabotulinumtoxinB 4,000 U.16 Conversely,
a recent small crossover study reported a lack of superiority of
incobotulinumtoxinA 100 U vs placebo 1 month post in-
jection for treatment of drooling in patients with PD.36
However, we have shown persistence of efficacy at week 16
post injection, suggesting that a crossover design may not be
appropriate within this time frame.
In the present study, treatment with incobotulinumtoxinA
100 U resulted in improvement in sialorrhea symptoms
measured by uSFR, GICS, and DSFS 4 weeks post treatment
that was greater than placebo and maintained at weeks 8 and
12. A lasting effect greater than placebo was also observed at
week 16 (the last observation point in the MP), suggesting
a duration of efficacy of incobotulinumtoxinA of at least 16
weeks and benefit to the patient that may extend beyond 4
months after the initial injection. The results of a similarly
designed placebo-controlled study showed significant im-
provement from baseline vs placebo in uSFR and global im-
pression of change, measured using the Clinical Global
Impression of Change scale, 4 weeks post treatment with
2,500 U or 3,500 U rimabotulinumtoxinB.37 The authors
noted that significant improvements in uSFR (measured by
collection of expectorated saliva in preweighed paper cups,
rather than by direct collection using absorbent swabs as in
the present study) in those treated with 3,500 U, and differ-
ences in the Clinical Global Impression of Change in those
treated with 2,500 U, were maintained up to week 13.37
In the present study, the effects of incobotulinumtoxinA 100 U
were clear for the coprimary endpoints; the efficacy of the 75 U
dose was less pronounced and may be delayed, reaching a re-
sponse threshold at a later time point, comparedwith the 100U
dose. Significant improvements in uSFR and differences in
patients’ GICS score occurred at 8 and 12 weeks post treat-
ment, potentially indicating a dose-dependent efficacy profile
and a viable treatment option in clinical practice.
This pivotal phase III study showed that incobotulinumtox-
inA (75 U and 100 U) was well tolerated for the treatment of
sialorrhea in neurologic disorders. Treatment-related AEs
occurred at a similar frequency in patients who received pla-
cebo and incobotulinumtoxinA 75 and 100 U. The most
frequently observed treatment-related AEs in the active
treatment groups were dry mouth and dysphagia, which oc-
curred at low frequency despite being common complications
in patients with PD.28,38,39 The slightly higher incidence of
dry mouth and dysphagia in the 75 U group compared with
100 Umay reflect the patients’ underlying medical history and
preexisting conditions. Of note, patients on concomitant
anticholinergics did not report dry mouth; an additive effect
was not obvious. Furthermore, there was no increased in-
cidence of AESIs potentially indicative of toxin spread with
increasing incobotulinumtoxinA dose, and no new safety
concerns were reported.
The strengths of the current study include the randomized,
double-blind, placebo-controlled study design and the in-
clusion of 2 incobotulinumtoxinA doses. One limitation of the
present study was the patient selection. It was initially
intended that the study population should contain at least
20% of patients from each of the etiologic subgroups (PD and
atypical parkinsonism; stroke; TBI) and specialized study
centers were selected to achieve this balance. However,
patients with non-PD neurologic conditions, such as atypical
parkinsonism disorders (including multiple system atrophy
and progressive supranuclear palsy), may experience a wider
spectrum of other symptoms, decreased mobility, and falls40
that may affect their participation in such studies. Therefore,
as incobotulinumtoxinA treatment for sialorrhea is not spe-
cific to a particular disease type, and to achieve the planned
sample size, this initial restriction was not enforced, and
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hence, as expected, the majority of patients had sialorrhea due
to PD. Low numbers of patients with sialorrhea due to stroke
or ALS were also included in previous small pilot studies.31,32
The data presented here support the utility of incobotuli-
numtoxinA 100 U as an effective and well-tolerated treatment
of chronic sialorrhea in adult patients. The high remaining
efficacy at 16 weeks post injection suggests a duration of
efficacy and benefit to the patients lasting at least 16 weeks.
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